Jury Hits AngioDynamics With Patent-Infringement Verdict
24 November 2022 - 3:11AM
Dow Jones News
By Colin Kellaher
AngioDynamics Inc. suffered another setback in its long-running
legal tussle with C.R. Bard Inc., as a Delaware jury found that
some of the medical-device company's implantable port products
infringe certain U.S. patents held by the Becton Dickinson Co.
unit.
In a filing with the U.S. Securities and Exchange Commission,
AngioDynamics said it strongly disagrees with the verdict and that
it plans to pursue all available remedies and defenses, including
post-trial motions and appeals.
The Latham, N.Y., company also noted that the issue of damages
was bifurcated by the court during the one-week trial and will be
decided by a jury in a separate proceeding.
The verdict follows last month's loss by AngioDynamics in an
antitrust lawsuit against C.R. Bard. In that case, a New York jury
dismissed claims by AngioDynamics that Bard restrained competition
in the U.S. by tying sales of its tip location systems to sales of
its percutaneously inserted central catheters. AngioDynamics has
said it is considering an appeal.
C.R. Bard initially launched its patent litigation against
AngioDynamics in early 2012. AngioDynamics on Wednesday said
several issues remain to be decided by the judge in the Delaware
case, and that the appeals process could extend over several
years.
Shares of AngioDynamics were down 7.2% to $13.59 Wednesday
morning.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 23, 2022 10:56 ET (15:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Apr 2023 to Apr 2024